Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Express Scripts
McKinsey
AstraZeneca
Dow

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,514,531

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,514,531 protect, and when does it expire?

Patent 6,514,531 protects AMBIEN CR and is included in one NDA.

Protection for AMBIEN CR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-three patent family members in twenty-seven countries.

Summary for Patent: 6,514,531
Title: Controlled-release dosage forms comprising zolpidem or a salt thereof
Abstract:The present invention relates to controlled-release dosage forms of zolpidem or salts thereof adapted to release zolpidem over a predetermined time period, according to a biphasic profile of dissolution, where the first phase is an immediate release phase and the second phase is a prolonged release phase and particular embodiments thereof intended to avoid abuse.
Inventor(s): Alaux; Gerard (Beynes, FR), Lewis; Gareth (Dourdan, FR), Andre; Frederic (Antony, FR)
Assignee: Sanofi-Synthelabo (Paris, FR)
Application Number:09/857,154
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,514,531
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Device; Composition;

Drugs Protected by US Patent 6,514,531

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sanofi Aventis Us AMBIEN CR zolpidem tartrate TABLET, EXTENDED RELEASE;ORAL 021774-002 Sep 2, 2005 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Sanofi Aventis Us AMBIEN CR zolpidem tartrate TABLET, EXTENDED RELEASE;ORAL 021774-001 Sep 2, 2005 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,514,531

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
98403037Dec 04, 1998
PCT Information
PCT FiledDecember 01, 1999PCT Application Number:PCT/EP99/10454
PCT Publication Date:June 15, 2000PCT Publication Number: WO00/33835

International Family Members for US Patent 6,514,531

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 021535   Start Trial
Austria 290861   Start Trial
Australia 2539900   Start Trial
Australia 771902   Start Trial
Brazil 9915939   Start Trial
Canada 2391983   Start Trial
China 1212838   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Johnson and Johnson
Express Scripts
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.